BU-NOT-SET

CONTACT US
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
  • Drug substance
Eyes
Insight
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
  • Industry trends
Eyes
Insight
Women in leadership
  • Corporate
Eyes
Insight
The state of the oral solid dose development and manufacturing market
  • Drug product
Eyes
Insight
Characterising APIs is Essential for Combo Drug Formulations
  • Drug substance
Eyes
Insight
Outsourcing stability testing
  • Analytical chemistry
Eyes
Insight
Brexit: What’s next for UK pharma?
  • Industry trends
Eyes
Insight
Navigating approval filings choppy international waters
  • Drug substance
Eyes
Insight
Regulatory requirements for drug substances
  • Drug substance
Product check
Insight
Insight
  • Analytical chemistry
The QbD approach: Key advantages in clinical and commercial phases
Report
  • Sustainability
Sustainability report 2020
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies
Fact sheet
  • Analytical chemistry
Extractables & leachables testing
Insight
  • Industry trends
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
Insight
  • Industry trends
Global expansion in the CDMO field